시장보고서
상품코드
1426127

세계의 약물전달 시스템 시장 : 제품별, 투여 경로별, 용도별, 최종사용자별, 지역별, 기회 및 예측(2017-2031년)

Drug Delivery Systems Market Assessment, By Product, By Route of Administration, By Application, By End-user, By Region, Opportunities and Forecast, 2017-2031F

발행일: | 리서치사: Market Xcel - Markets and Data | 페이지 정보: 영문 225 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    


■ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

전 세계 약물전달 시스템 시장 규모는 예측 기간 동안 복합 연간 성장률(CAGR) 9.14%로 성장할 전망이고 2023년 1,516억 달러에서 2031년에 3,051억 9,000만 달러 규모로 성장할 것으로 예측됩니다.

세계 약물전달 시스템 시장을 형성하는 역학은 만성 질환의 확대, 자기 투여 장치 수요 급증, 기술의 진보, 노인 인구 증가, 생물 제제와 고분자 의약품의 융성, 투자 증가, 공동 파트너십, 신흥 국가 시장의 급성장, 지원 규제 프레임 워크, 맞춤형 의료 등장 등 다양한 요소가 포함되어 있습니다.

세계 약물전달 시스템 시장은 다양한 요인에 의해 큰 변혁기를 맞이하고 있습니다. 암, 당뇨병, 심혈관 질환과 같은 만성 질환의 이환율이 증가하면 보다 효율적이고 목표를 이루는 약물 전달 방법의 필요성을 강조하여 매우 중요한 추진력이 되었습니다. 또한 치료의 편의성과 자기 관리 능력이 요구되고 있으며, 자기 투여 도구에 대한 환자의 선호도가 현저하게 급증하고 있습니다. 또한, 기술의 끊임없는 진보는 약물전달 시스템을 강화하는 데 중요한 역할을 담당하고 있습니다. 또한 노인 인구 증가는 노인을 위해 특별히 설계된 재단사의 배달 시스템에 대한 수요를 두드러지게합니다.

또한 각국 정부는 세계 약물전달 시스템 시장의 확대를 촉진하기 위해 다양한 프로그램을 적극적으로 실시했습니다. 이러한 활동에는 R&D에 인센티브를 부여하고, 규제 프로세스를 단순화하고 승인을 가속화하고, 혁신을 촉진하기 위해 재정 지원 및 보조금을 제공하는 등 다양한 접근법이 포함됩니다. 또한 일부 정부는 교육기관, 산업계, 연구센터간의 제휴를 육성하고, 기술 이전을 완화하며, 고급 약물전달 기술에 대한 투자를 장려하고 있습니다.

본 보고서에서는 세계 약물전달 시스템 시장을 조사했으며, 시장 정의와 개요, 시장 규모 추이와 예측, 각종 구분, 지역별 상세 분석, 산업 구조, 시장 성장에 대한 영향요인 분석, 케이스 스터디, 경쟁 구도, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 조사 방법

제2장 프로젝트의 범위와 정의

제3장 주요 요약

제4장 세계 약물전달 시스템 시장 전망

  • 시장 규모와 예측
  • 제품별
    • 프리필드 주사기
    • 자동 주사기
    • 주입 펌프
    • 정량 흡입기(MDI)
    • 분무기
    • 점비약
    • 스포이드
    • 자궁내 피임구(IUD)
  • 투여 경로별
    • 폐에의 약물전달
    • 경점막 약물 전달
    • 경비약 약물 전달
    • 경구 약물 전달
    • 국소 약물전달
    • 매립형 약물전달
    • 주사별 약물전달
    • 안과 약물 전달
  • 용도별
    • 자가면역질환
    • 심혈관 질환
    • 감염증
    • 호흡기 질환
    • 중추 신경계 질환
    • 당뇨병
    • 기타
  • 최종 사용자별
    • 병원
    • 외래수술센터(ASC)
    • 재택 케어
    • 진단센터
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 남미
    • 아시아태평양
    • 중동 및 아프리카
  • 기업별 시장 점유율

제5장 세계 약물전달 시스템 시장 전망 : 지역별

  • 북미
  • 유럽
  • 남미
  • 아시아태평양
  • 중동 및 아프리카

제6장 시장 매핑

  • 제품별
  • 투여 경로별
  • 용도별
  • 최종 사용자별
  • 지역별

제7장 거시적 환경과 산업 구조

  • 수급 분석
  • 수출입 분석
  • 밸류체인 분석
  • PESTEL 분석
  • Porter's Five Forces 분석

제8장 시장 역학

  • 성장 촉진요인
  • 성장 억제요인(과제· 억제)

제9장 규제 프레임워크과 혁신

  • 임상시험
  • 특허의 정세
  • 규제 당국의 승인
  • 혁신/최신기술

제10장 주요 기업의 정세

  • 시장 리더 주요 5개사의 경쟁 매트릭스
  • 시장 리더 상위 5개사 시장 수익 분석
  • M&A조인트 벤처(해당하는 경우)
  • SWOT 분석(참가 5사)
  • 특허 분석(해당되는 경우)

제11장 가격 분석

제12장 사례 연구

제13장 주요 기업의 전망

  • Sharps Technology Inc.
  • Becton, Dickinson and Company
  • Cardinal Health
  • Novo Nordisk A/S
  • Terumo Corporation
  • Insulet Corporation
  • Enable Injections, Inc.
  • Bespak Europe Ltd.
  • West Pharmaceutical Services, Inc.
  • Novartis International AG
  • Merck & Co., Inc.
  • Sanofi SA

제14장 전략적 제안

제15장 당사에 대해서 면책사항

BJH 24.02.26

Global drug delivery systems market is projected to witness a CAGR of 9.14% during the forecast period 2024-2031, growing from USD 151.6 billion in 2023 to USD 305.19 billion in 2031. The dynamics shaping the global drug delivery systems market encompass a spectrum of elements, such as the escalation of chronic diseases, the surge in demand for self-administration devices, advancements in technology, the growth of the geriatric population, the prominence of biologics and large molecule drugs, increased investment, collaborative partnerships, the burgeoning market in emerging economies, supportive regulatory frameworks, and the advent of personalized medicine.

The global drug delivery systems market is in a phase of significant transformation, driven by a diverse range of influential factors. The escalating incidence of chronic diseases, such as cancer, diabetes, and cardiovascular conditions, serve as a pivotal force, stimulating the need for more efficient and targeted drug delivery methods. Concurrently, there's a notable surge in patient preference for self-administration tools, aiming for convenience and self-management in their therapies. Furthermore, the continual advancement of technology assumes a crucial role in enhancing drug delivery systems. Additionally, the increasing elderly population, with its unique healthcare requirements, underscores the demand for tailor-made delivery systems designed specifically for older individuals in the global drug delivery systems market.

The global drug delivery systems market configuration is further influenced by the prominence of biologics and large molecule drugs, necessitating sophisticated delivery platforms to ensure efficient administration. Collaborative alliances between pharmaceutical firms and research institutions drive innovation, accelerating the creation and commercialization of pioneering delivery systems. Concurrently, the burgeoning healthcare markets in developing economies present unexplored avenues for expansion, buoyed by supportive regulatory frameworks that facilitate research and development ventures. The emergence of personalized medicine, focused on customized therapies tailored to individual patient needs, signifies a substantial shift, fueling the quest for personalized drug delivery solutions on a global scale and boosting the global drug delivery systems market.

Surge in Demand for Self-Administration Devices

The rising demand for self-administration devices is a key catalyst driving the global drug delivery systems market expansion. Patients increasingly desire independence and ease in handling their treatments, resulting in a noticeable uptick in the uptake of such devices. These self-administration solutions, including injectable pens, wearable technologies, and other user-friendly tools, grant patients' greater autonomy in managing their therapies, simplifying the treatment process. This upsurge mirrors a change in patient preferences and underscores a fundamental shift in healthcare delivery, highlighting the significance of personalized and convenient treatment choices. As a result, the market for drug delivery systems is experiencing substantial growth, fueled by the escalating preference for self-administration devices among healthcare consumers worldwide.

Increased Investments

Numerous corporations are reinforcing their financial commitments in the global drug delivery systems sector, demonstrated through the creation of fresh production facilities. This strategic endeavor entails the construction of cutting-edge sites geared towards manufacturing sophisticated drug delivery systems. By expanding their manufacturing prowess, firms endeavor to satisfy increasing market needs, pioneer inventive delivery approaches, and streamline production efficiency. These investments reflect a dedication to augment research, development, and production capabilities, enabling the companies to seize the burgeoning prospects within the ever-changing pharmaceutical arena.

For instance, in March 2023, Genixus, a firm dedicated to producing and creating drug delivery systems, declared the completion of a new manufacturing facility in Concord, N.C. The site is equipped with automated manufacturing and state-of-the-art technology specifically designed to bolster the KinetiX syringe platform and broaden its product range. This increase in manufacturing capability is a direct response to the market's call for ready-to-administer (RTA) syringes.

Government Initiatives

Governments globally are proactively executing various programs to nurture the expansion of the worldwide drug delivery systems market. These initiatives involve diverse approaches like incentivizing research and development, simplifying regulatory processes to hasten approvals, and offering financial aid or grants to spur innovation. Furthermore, certain governments are cultivating partnerships between educational institutions, industries, and research centers, easing the transfer of technology, and encouraging investments in sophisticated drug delivery technologies. These extensive actions reflect a unified endeavor to propel progress in drug delivery systems, aiming for enhanced treatments, improved patient results, and meeting evolving healthcare demands globally.

For example, in February 2021, the Union Cabinet of India approved the Production Linked Incentive (PLI) initiative tailored for the pharmaceutical sector. The scheme aims to elevate India's manufacturing capacities by augmenting investments and production within the sector, fostering the expansion of product diversity towards high-value pharmaceutical goods. Additionally, the scheme seeks to cultivate globally competitive entities in India, empowering them to expand in scope and magnitude by integrating advanced technology, thus enabling their integration into global value chains.

Growing demand for Autoinjectors

There's a notable increase in the global drug delivery systems market's interest in autoinjectors. These tools facilitate patient-friendly, self-administered medication, especially advantageous for individuals needing regular injections. The escalating incidence of chronic illnesses and the preference for home-based healthcare solutions play a role in driving this escalated need. Autoinjectors ensure accuracy in dosing, ease of use, and a decrease in medical mistakes, promoting patient adherence to treatments. Additionally, technological advancements, improvements in design, and the widening application of injectable medications in various therapeutic areas contribute to the growing acceptance of autoinjectors. Consequently, they emerge as a pivotal driver in the expansion of the drug delivery systems market.

For instance, in September 2023, Ypsomed, a Swiss medical technology firm, disclosed a prolonged supply agreement with Novo Nordisk for autoinjectors. This partnership highlights the advantageous impact of the Danish pharmaceutical company's weight-loss drug business on firms specializing in pharmaceutical services. Ypsomed plans to increase its production capacities in the upcoming years, with Novo Nordisk playing a substantial role by investing in the added production infrastructure.

Drug Delivery Systems for Diabetes

The escalating demand for drug delivery systems tailored for diabetes treatment significantly drives growth within the global drug delivery systems market. Diabetes, a prevalent chronic condition, requires consistent and precise medication administration. This heightened demand stems from the need for effective delivery mechanisms ensuring optimized drug dosing, improved patient compliance, and reduced treatment-associated complications. With advancements in diabetes management and the expansion of therapeutic options, the market experiences an upsurge in innovative drug delivery systems catering specifically to diabetic patients, thereby contributing substantially to the market's expansion and evolution.

For example, Terumo India, the Indian division of Terumo Corporation, a prominent global player in medical technology, unveiled an insulin syringe on November 14, 2023. This sterile delivery device caters to patients needing frequent insulin injections, elevating standards for patient comfort and adherence to therapy.

Future Market Scenario (2024-2031F)

The future prospects of the global drug delivery systems market display a high level of promise. Several factors contribute to this positive outlook, notably ongoing technological advancements that consistently refine drug delivery techniques. These innovations result in more accurate, targeted, and efficient medication administration, elevating treatment effectiveness, while reducing potential side effects. Moreover, the escalating prevalence of chronic diseases like cancer, diabetes, and cardiovascular ailments worldwide drives the demand for advanced drug delivery systems. This need is amplified by an increasingly aging population requiring specialized treatment modalities. Additionally, the industry's response to global health crises, such as the COVID-19 pandemic, has expedited research and development, yielding rapid progress in vaccine delivery methods and therapeutics. The continual expansion of healthcare infrastructure in emerging economies and the emphasis on personalized medicine further propels the ongoing evolution and potential expansion of the global drug delivery systems market.

Key Players Landscape and Outlook

The global drug delivery systems market is currently witnessing a series of acquisitions. These strategic moves involve companies acquiring or merging with other entities to expand their product portfolios, enhance market presence, or access novel technologies. Acquisitions offer opportunities for companies to consolidate their positions, capitalize on synergies, and gain competitive advantages. They facilitate access to new markets, diversification of offerings, and acceleration of innovation by integrating complementary expertise. These transactions signify a dynamic phase within the drug delivery systems industry, aimed at reinforcing market foothold and fostering growth through strategic partnerships and expansions.

For instance, in July 2023, Novartis, a Swiss multinational pharmaceutical corporation, completed the acquisition of DTx Pharma, a startup specializing in RNA medicine delivery, for $500 million. DTx Pharma's Fatty Acid Ligand Conjugated Oligonucleotide (FALCON) platform enables the delivery of siRNA therapeutics outside the liver.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Drug Delivery Systems Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Product
    • 4.2.1. Prefilled Syringes
    • 4.2.2. Autoinjectors
    • 4.2.3. Infusion Pumps
    • 4.2.4. Metered Dose Inhalers (MDIs)
    • 4.2.5. Nebulizers
    • 4.2.6. Nasal Sprays
    • 4.2.7. Eyedroppers
    • 4.2.8. Intrauterine Devices (IUDs)
  • 4.3. By Route of Administration
    • 4.3.1. Pulmonary Drug Delivery
    • 4.3.2. Transmucosal Drug Delivery
    • 4.3.3. Nasal Drug Delivery
    • 4.3.4. Oral Drug Delivery
    • 4.3.5. Topical Drug Delivery
    • 4.3.6. Implantable Drug Delivery
    • 4.3.7. Injectable Drug Delivery
    • 4.3.8. Ocular Drug Delivery
  • 4.4. By Application
    • 4.4.1. Autoimmune Diseases
    • 4.4.2. Cardiovascular Diseases
    • 4.4.3. Cancer
    • 4.4.4. Infectious Diseases
    • 4.4.5. Respiratory Diseases
    • 4.4.6. Central Nervous System Diseases
    • 4.4.7. Diabetes
    • 4.4.8. Others
  • 4.5. By End-user
    • 4.5.1. Hospitals
    • 4.5.2. Ambulatory Surgical Centers
    • 4.5.3. Home Care Settings
    • 4.5.4. Diagnostic Centers
    • 4.5.5. Others
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. South America
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global Drug Delivery Systems Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Product
      • 5.1.2.1. Prefilled Syringes
      • 5.1.2.2. Autoinjectors
      • 5.1.2.3. Infusion Pumps
      • 5.1.2.4. Metered Dose Inhalers (MDIs)
      • 5.1.2.5. Nebulizers
      • 5.1.2.6. Nasal Sprays
      • 5.1.2.7. Eyedroppers
      • 5.1.2.8. Intrauterine Devices (IUDs)
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Pulmonary Drug Delivery
      • 5.1.3.2. Transmucosal Drug Delivery
      • 5.1.3.3. Nasal Drug Delivery
      • 5.1.3.4. Oral Drug Delivery
      • 5.1.3.5. Topical Drug Delivery
      • 5.1.3.6. Implantable Drug Delivery
      • 5.1.3.7. Injectable Drug Delivery
      • 5.1.3.8. Ocular Drug Delivery
    • 5.1.4. By Application
      • 5.1.4.1. Autoimmune Diseases
      • 5.1.4.2. Cardiovascular Diseases
      • 5.1.4.3. Cancer
      • 5.1.4.4. Infectious Diseases
      • 5.1.4.5. Respiratory Diseases
      • 5.1.4.6. Central Nervous System Diseases
      • 5.1.4.7. Diabetes
      • 5.1.4.8. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Hospitals
      • 5.1.5.2. Ambulatory Surgical Centers
      • 5.1.5.3. Home Care Settings
      • 5.1.5.4. Diagnostic Centers
      • 5.1.5.5. Others
    • 5.1.6. United States*
      • 5.1.6.1. Market Size & Forecast
      • 5.1.6.1.1. Value
      • 5.1.6.1.2. Volume
      • 5.1.6.2. By Product
      • 5.1.6.2.1. Prefilled Syringes
      • 5.1.6.2.2. Autoinjectors
      • 5.1.6.2.3. Infusion Pumps
      • 5.1.6.2.4. Metered Dose Inhalers (MDIs)
      • 5.1.6.2.5. Nebulizers
      • 5.1.6.2.6. Nasal Sprays
      • 5.1.6.2.7. Eyedroppers
      • 5.1.6.2.8. Intrauterine Devices (IUDs)
      • 5.1.6.3. By Route of Administration
      • 5.1.6.3.1. Pulmonary Drug Delivery
      • 5.1.6.3.2. Transmucosal Drug Delivery
      • 5.1.6.3.3. Nasal Drug Delivery
      • 5.1.6.3.4. Oral Drug Delivery
      • 5.1.6.3.5. Topical Drug Delivery
      • 5.1.6.3.6. Implantable Drug Delivery
      • 5.1.6.3.7. Injectable Drug Delivery
      • 5.1.6.3.8. Ocular Drug Delivery
      • 5.1.6.4. By Application
      • 5.1.6.4.1. Autoimmune Diseases
      • 5.1.6.4.2. Cardiovascular Diseases
      • 5.1.6.4.3. Cancer
      • 5.1.6.4.4. Infectious Diseases
      • 5.1.6.4.5. Respiratory Diseases
      • 5.1.6.4.6. Central Nervous System Diseases
      • 5.1.6.4.7. Diabetes
      • 5.1.6.4.8. Others
      • 5.1.6.5. By End-user
      • 5.1.6.5.1. Hospitals
      • 5.1.6.5.2. Ambulatory Surgical Centers
      • 5.1.6.5.3. Home Care Settings
      • 5.1.6.5.4. Diagnostic Centers
      • 5.1.6.5.5. Others
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia-Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Product
  • 6.2. By Route of Administration
  • 6.3. By Application
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Sharps Technology Inc.
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Becton, Dickinson and Company
  • 13.3. Cardinal Health
  • 13.4. Novo Nordisk A/S
  • 13.5. Terumo Corporation
  • 13.6. Insulet Corporation
  • 13.7. Enable Injections, Inc.
  • 13.8. Bespak Europe Ltd.
  • 13.9. West Pharmaceutical Services, Inc.
  • 13.10. Novartis International AG
  • 13.11. Merck & Co., Inc.
  • 13.12. Sanofi S.A.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제